Cipla Share Price Analyzed

Key Points

• Cipla’s stock dropped significantly, hitting a 9-month low.
• The drop was due to a temporary halt in Lanreotide production.
• USFDA found issues at a supplier’s factory in Greece.
• Production will restart in early 2027, but with limited supply.
• Lanreotide is a key product, contributing significantly to Cipla’s revenue.
• This disruption could lead to a short-term loss in revenue and profits.

Cipla’s stock price fell sharply on Friday, reaching a low of ₹1,367.80. This is the lowest price it’s been at in almost a year! The reason? They stopped making one of their important medicines, Lanreotide.

This happened because the US government (USFDA) noticed problems at a factory that makes Lanreotide for Cipla. They found nine issues during an inspection in November 2025.

Because of these problems, Cipla had to stop making Lanreotide. They expect to start making it again in early 2027, but for a while, it will be hard to get enough.

Lanreotide is a big deal for Cipla – it’s one of their top three medicines in the United States. Experts say that stopping production could cause a temporary loss in money and profits.

The stock price has fallen by 11% in the last 7 days, and analysts predict it will continue to be affected until the production is back on track. Cipla is working to fix the problems quickly and get the medicine back into supply as soon as possible.

Businesses react to changes; investing requires careful consideration of these shifts.